5 Result(s)

Article

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Deborah JL Wong, Lidia Robert, Mohammad S Atefi, Amanda Lassen… in Molecular Cancer (2015)

Article

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investig...

Mohammad Atefi, Bjoern Titz, Earl Avramis, Charles Ng, Deborah JL Wong… in Molecular Cancer (2015)

Article

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

In melanoma, dysregulation of the MAPK pathway, usually via BRAF ^V600 or NRAS ^Q61 somatic mutations, leads to constitutive ERK signali...

Deborah JL Wong, Lidia Robert, Mohammad S Atefi, Amanda Lassen… in Molecular Cancer (2014)

Article

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway c...

Amanda Lassen, Mohammad Atefi, Lidia Robert, Deborah JL Wong… in Molecular Cancer (2014)

Article

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2.

Erika von Euw, Mohammad Atefi, Narsis Attar, Connie Chu… in Molecular Cancer (2012)